Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Adjunctive Brexpiprazole in Bipolar I Depression
NCT04569448Phase 3Recruiting
- Sponsor
- Douglas Mental Health University Institute
- Start
- May 2021
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of brexpiprazole orally disintegrating tablet in bipolar disorder (BD), sponsored by Douglas Mental Health University Institute. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 8 weeks. Started May 2021; status: recruiting.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT04569448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04569448.